Canaccord Genuity Maintains a 'Buy' on Medifast (MED); Limited Downside, But Waiting For Clarity To Upside

Canaccord Genuity maintains a 'Buy' on Medifast (NYSE: MED) price target raised from $16 to $19.

Analyst, Scott Van Winkle, said, "We maintain our rating as we look for visibility on health coach trends in the Take Shape for Life channel and as earnings pressure from the clinic expansion subsides...At 13x our forward earnings estimate (ex-cash) and 6x our EBITDA forecast, we believe the shares should have limited downside"

For an analyst ratings summary and ratings history on Medifast click here. For more ratings news on Medifast click here.

Shares of Medifast closed at $18.35 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Diana Shipping drops bid for Genco after price demands spike to $36.91
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49